Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2PRECISE: Secukinumab in Palmoplantar Pustular Psoriasis
NCT02008890Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2013
- Primary completion
- Nov 2014
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of secukinumab in Palmoplantar Pustular Psoriasis (PPPP), sponsored by Novartis. Started Dec 2013; status: completed.
02
Drugs
secukinumab
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)
Beyond the preview
Go deeper on NCT02008890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02008890.